Insulet Corporation Company Profile (NASDAQ:PODD)

About Insulet Corporation (NASDAQ:PODD)

Insulet Corporation logoInsulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM). The Omnipod System features two discreet devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Omnipod System is a discreet two part design, the Omnipod device (Pod) and the PDM that eliminates the need for the external tubing required with conventional pumps. The Pod is a self-adhesive device that the patient fills with insulin and wears directly on the body.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Prosthetics
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:PODD
  • CUSIP: 45784P10
  • Web: www.insulet.com
Capitalization:
  • Market Cap: $3.57531 billion
  • Outstanding Shares: 58,059,000
Average Prices:
  • 50 Day Moving Avg: $58.62
  • 200 Day Moving Avg: $50.19
  • 52 Week Range: $30.69 - $62.82
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -406.80
  • P/E Growth: -4.86
Sales & Book Value:
  • Annual Revenue: $409.92 million
  • Price / Sales: 8.64
  • Book Value: $1.12 per share
  • Price / Book: 54.48
Profitability:
  • EBITDA: $9.31 million
  • Net Margins: -7.30%
  • Return on Equity: -46.74%
  • Return on Assets: -6.61%
Debt:
  • Debt-to-Equity Ratio: 5.27%
  • Current Ratio: 7.06%
  • Quick Ratio: 6.35%
Misc:
  • Average Volume: 425,035 shs.
  • Beta: 1.5
  • Short Ratio: 11.44
 

Frequently Asked Questions for Insulet Corporation (NASDAQ:PODD)

What is Insulet Corporation's stock symbol?

Insulet Corporation trades on the NASDAQ under the ticker symbol "PODD."

How were Insulet Corporation's earnings last quarter?

Insulet Corporation (NASDAQ:PODD) announced its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.13) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.13). The company had revenue of $110 million for the quarter, compared to the consensus estimate of $106.23 million. Insulet Corporation had a negative net margin of 7.30% and a negative return on equity of 46.74%. The company's quarterly revenue was up 26.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.08) EPS. View Insulet Corporation's Earnings History.

When will Insulet Corporation make its next earnings announcement?

Insulet Corporation is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Insulet Corporation.

Where is Insulet Corporation's stock going? Where will Insulet Corporation's stock price be in 2017?

15 analysts have issued twelve-month price objectives for Insulet Corporation's shares. Their forecasts range from $38.00 to $74.00. On average, they anticipate Insulet Corporation's stock price to reach $55.46 in the next twelve months. View Analyst Ratings for Insulet Corporation.

What are analysts saying about Insulet Corporation stock?

Here are some recent quotes from research analysts about Insulet Corporation stock:

  • 1. According to Zacks Investment Research, "INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. " (10/12/2017)
  • 2. Northland Securities analysts commented, "Epizyme’s loss per share of $0.48 was less than our estimated $0.66. This resulted from higher than estimated revenue, which was $10 million compared to our estimated $0.6 million, and resulted from a milestone payment. Expenses were in line with expectations. Our outlook for 2017-22 remains basically unchanged. We are adjusting our 2017 estimates to reflect the milestone payment in this quarter." (8/4/2017)
  • 3. Jefferies Group LLC analysts commented, "PODD's 4Q sales were $3mn above guidance with strength in all areas: US +17%, OUS +35%, and DD +34%. New patient starts in 2016 at +13% missed the +20% annual target reiterated just last Q. To this end, mgmt highlighted that a more important metric to pay attention to is the 15k total patient adds (vs. 13k in 2015) and the installed base grew by 15%. Despite 670G around the corner, Insulet remains largely dismissive of the launch." (2/28/2017)
  • 4. Wedbush analysts commented, " Insulet posted robust 4Q16 results and issued healthy 2017 guidance, signaling confidence in the overall growth of its diabetes and drug delivery franchises despite a more competitive diabetes landscape. PODD's relatively new management continues to fire on all cylinders with betterthan-expected revenues across all three of its business segments and solid gross margin expansion. The main takeaways from the quarter were continued strength within the company's diabetes franchises (US and OUS), the success of its drug delivery segment, and the confidence that momentum should continue in 2017" (2/28/2017)

Who are some of Insulet Corporation's key competitors?

Who are Insulet Corporation's key executives?

Insulet Corporation's management team includes the folowing people:

  • Patrick J. Sullivan, Chairman of the Board, Chief Executive Officer
  • Shacey Petrovic, President, Chief Operating Officer
  • Michael L. Levitz, Chief Financial Officer, Senior Vice President, Treasurer
  • Bradley B. Thomas, Executive Vice President - Human Resources and Organizational Development
  • David Colleran J.D., Senior Vice President, General Counsel, Secretary
  • Aiman Abdel-Malek Ph.D., Senior Vice President - Advanced Technology and Engineering
  • Charles Alpuche, Senior Vice President - Global Manufacturing and Operations
  • Michael Spears, Senior Vice President - Quality and Regulatory Affairs
  • Bret Christensen, Chief Commercial Officer
  • Jessica Hopfield Ph.D., Lead Independent Director

Who owns Insulet Corporation stock?

Insulet Corporation's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Nationwide Fund Advisors (0.22%), Tributary Capital Management LLC (0.04%), Fisher Asset Management LLC (0.02%), Fox Run Management L.L.C. (0.01%) and Strs Ohio (0.01%). Company insiders that own Insulet Corporation stock include Bradley A Thomas, Charles Alpuche, Daniel J Levangie, David A Lemoine, Jessica Hopfield, Joseph S Zakrzewski, Michael P Spears, Patrick J Sullivan and Regina O Sommer. View Institutional Ownership Trends for Insulet Corporation.

Who sold Insulet Corporation stock? Who is selling Insulet Corporation stock?

Insulet Corporation's stock was sold by a variety of institutional investors in the last quarter, including Nationwide Fund Advisors, Tributary Capital Management LLC and Fisher Asset Management LLC. Company insiders that have sold Insulet Corporation stock in the last year include David A Lemoine, Joseph S Zakrzewski and Regina O Sommer. View Insider Buying and Selling for Insulet Corporation.

Who bought Insulet Corporation stock? Who is buying Insulet Corporation stock?

Insulet Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C. and Strs Ohio. Company insiders that have bought Insulet Corporation stock in the last two years include Bradley A Thomas, Charles Alpuche, Jessica Hopfield, Michael P Spears and Patrick J Sullivan. View Insider Buying and Selling for Insulet Corporation.

How do I buy Insulet Corporation stock?

Shares of Insulet Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insulet Corporation's stock price today?

One share of Insulet Corporation stock can currently be purchased for approximately $61.02.


MarketBeat Community Rating for Insulet Corporation (NASDAQ PODD)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  396 (Vote Outperform)
Underperform Votes:  345 (Vote Underperform)
Total Votes:  741
MarketBeat's community ratings are surveys of what our community members think about Insulet Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Insulet Corporation (NASDAQ:PODD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $55.46 (9.11% downside)
Consensus Price Target History for Insulet Corporation (NASDAQ:PODD)
Price Target History for Insulet Corporation (NASDAQ:PODD)
Analysts' Ratings History for Insulet Corporation (NASDAQ:PODD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/13/2017Robert W. BairdSet Price TargetBuy$65.00N/AView Rating Details
10/12/2017Leerink SwannReiterated RatingOutperform$65.00 -> $74.00N/AView Rating Details
10/10/2017WedbushReiterated RatingBuy$60.00 -> $65.00N/AView Rating Details
9/27/2017Canaccord GenuityReiterated RatingHold$50.00MediumView Rating Details
9/15/2017Barclays PLCInitiated CoverageOverweight -> Overweight$65.00LowView Rating Details
8/9/2017Jefferies Group LLCReiterated RatingBuy$48.00 -> $58.00LowView Rating Details
8/4/2017Oppenheimer Holdings, Inc.Set Price TargetHold$55.00LowView Rating Details
8/4/2017Northland SecuritiesReiterated RatingBuyLowView Rating Details
8/4/2017Cowen and CompanyReiterated RatingOutperform$52.00 -> $63.00HighView Rating Details
7/17/2017BTIG ResearchDowngradeBuy -> NeutralMediumView Rating Details
5/25/2017William BlairReiterated RatingOutperform -> OutperformLowView Rating Details
5/22/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$47.00LowView Rating Details
5/14/2017B. RileyReiterated RatingNeutral$44.00LowView Rating Details
2/27/2017Feltl & Co.DowngradeBuy -> HoldN/AView Rating Details
11/17/2016J P Morgan Chase & CoReiterated RatingHold$38.00N/AView Rating Details
5/16/2016Sterne Agee CRTReiterated RatingNeutralN/AView Rating Details
2/26/2016Benchmark Co.UpgradeHold -> Buy$30.00 -> $40.00N/AView Rating Details
11/2/2015Morgan StanleyInitiated CoverageEqual -> Equal Weight$32.00N/AView Rating Details
(Data available from 10/24/2015 forward)

Earnings

Earnings History for Insulet Corporation (NASDAQ:PODD)
Earnings by Quarter for Insulet Corporation (NASDAQ:PODD)
Earnings History by Quarter for Insulet Corporation (NASDAQ PODD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017($0.10)N/AView Earnings Details
8/3/2017Q2 2017($0.13)($0.13)$106.23 million$110.00 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.16)($0.17)$97.73 million$101.70 millionViewListenView Earnings Details
2/27/2017Q416($0.05)($0.16)$100.61 million$103.58 millionViewListenView Earnings Details
11/3/2016Q316($0.09)($0.05)$89.75 million$94.90 millionViewN/AView Earnings Details
8/3/2016Q216($0.17)($0.08)$81.10 million$87.30 millionViewN/AView Earnings Details
4/28/2016Q116($0.19)($0.19)$79.06 million$81.21 millionViewListenView Earnings Details
2/25/2016Q415($0.26)($0.48)$91.89 million$100.10 millionViewListenView Earnings Details
11/5/2015Q315($0.26)($0.33)$83.56 million$87.30 millionViewListenView Earnings Details
8/12/2015Q215($0.13)($0.27)$70.32 million$75.60 millionViewListenView Earnings Details
4/30/2015Q115($0.10)($0.21)$68.20 million$61.20 millionViewN/AView Earnings Details
2/26/2015Q414($0.04)($0.10)$73.52 million$72.60 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.06)$72.94 million$72.00 millionViewN/AView Earnings Details
5/7/2014Q114($0.06)($0.11)$68.47 million$69.20 millionViewN/AView Earnings Details
2/27/2014Q413($0.09)($0.04)$67.94 million$68.53 millionViewN/AView Earnings Details
11/7/2013Q313($0.16)($0.39)$62.01 million$61.10 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.19)($0.20)$60.47 million$60.09 millionViewN/AView Earnings Details
5/6/2013Q1 2013($0.21)($0.20)$57.26 million$57.40 millionViewN/AView Earnings Details
2/27/2013Q4 2012($0.21)($0.21)$59.12 million$57.80 millionViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.26)$54.93 million$54.80 millionViewN/AView Earnings Details
8/8/2012($0.25)($0.30)ViewN/AView Earnings Details
5/9/2012($0.28)($0.31)ViewN/AView Earnings Details
2/9/2012($0.26)($0.30)ViewN/AView Earnings Details
11/3/2011($0.25)($0.29)ViewN/AView Earnings Details
8/2/2011($0.21)($0.42)ViewN/AView Earnings Details
5/9/2011($0.22)($0.22)ViewN/AView Earnings Details
2/15/2011($0.26)($0.50)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Insulet Corporation (NASDAQ:PODD)
2017 EPS Consensus Estimate: ($0.46)
2018 EPS Consensus Estimate: ($0.09)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20178($0.23)($0.10)($0.15)
Q2 20178($0.16)($0.04)($0.12)
Q3 20178($0.13)($0.02)($0.09)
Q4 20178($0.11)($0.02)($0.09)
Q1 20185($0.11)$0.02($0.06)
Q2 20185($0.11)$0.05($0.02)
Q3 20184($0.10)$0.06$0.00
Q4 20184($0.09)$0.06($0.01)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Insulet Corporation (NASDAQ:PODD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Insulet Corporation (NASDAQ:PODD)
Insider Ownership Percentage: 2.60%
Insider Trades by Quarter for Insulet Corporation (NASDAQ:PODD)
Institutional Ownership by Quarter for Insulet Corporation (NASDAQ:PODD)
Insider Trades by Quarter for Insulet Corporation (NASDAQ:PODD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/6/2017Charles AlpucheEVPBuy2,500$58.08$145,200.00View SEC Filing  
5/16/2017Michael P. SpearsSVPBuy2,500$40.59$101,475.00View SEC Filing  
5/11/2017Bradley A. ThomasEVPBuy3,000$38.69$116,070.00View SEC Filing  
5/11/2017Jessica HopfieldDirectorBuy2,580$38.68$99,794.40View SEC Filing  
5/1/2017David A. LemoineDirectorSell1,524$43.40$66,141.60View SEC Filing  
3/13/2017Regina O. SommerDirectorSell40,000$45.00$1,800,000.00View SEC Filing  
3/6/2017David A. LemoineDirectorSell1,282$45.15$57,882.30View SEC Filing  
3/2/2017Joseph S. ZakrzewskiDirectorSell40,000$46.86$1,874,400.00View SEC Filing  
12/9/2016Charles AlpucheSVPBuy6,600$37.70$248,820.00View SEC Filing  
12/2/2016Patrick J. SullivanCEOBuy40,000$33.89$1,355,600.00View SEC Filing  
12/1/2016Bradley A. ThomasEVPBuy3,100$32.45$100,595.00View SEC Filing  
5/25/2016Regina O SommerDirectorSell8,019$30.42$243,937.98View SEC Filing  
5/18/2016Patrick J SullivanCEOBuy45,000$27.00$1,215,000.00View SEC Filing  
5/13/2016Bradley A ThomasEVPBuy2,975$26.63$79,224.25View SEC Filing  
5/5/2016Bradley A ThomasEVPBuy1,656$30.13$49,895.28View SEC Filing  
3/10/2016Daniel J LevangieInsiderSell12,299$30.89$379,916.11View SEC Filing  
3/7/2016Daniel J LevangieInsiderSell7,663$31.15$238,702.45View SEC Filing  
3/2/2016Jessica HopfieldDirectorBuy3,230$30.91$99,839.30View SEC Filing  
6/5/2015Patrick J SullivanCEOBuy10,000$29.39$293,900.00View SEC Filing  
5/28/2015Patrick J SullivanCEOBuy20,000$27.91$558,200.00View SEC Filing  
5/15/2015Timothy J ScannellDirectorBuy3,500$27.05$94,675.00View SEC Filing  
5/5/2015Bradley A ThomasEVPBuy1,000$27.26$27,260.00View SEC Filing  
5/5/2015Patrick RyanCOOBuy3,669$26.99$99,026.31View SEC Filing  
4/2/2015R Anthony DiehlGeneral CounselSell3,372$30.96$104,397.12View SEC Filing  
3/9/2015Patrick J SullivanCEOBuy10,000$31.93$319,300.00View SEC Filing  
3/2/2015Charles T LiamosDirectorSell4,000$32.00$128,000.00View SEC Filing  
2/12/2015Charles T LiamosDirectorSell4,000$32.00$128,000.00View SEC Filing  
1/2/2015Charles T LiamosDirectorSell4,000$46.08$184,320.00View SEC Filing  
11/3/2014Charles T LiamosDirectorSell4,000$42.95$171,800.00View SEC Filing  
10/1/2014Charles T LiamosDirectorSell4,000$36.58$146,320.00View SEC Filing  
10/1/2014R Anthony DiehlGeneral CounselSell1,250$36.59$45,737.50View SEC Filing  
9/10/2014Charles T LiamosDirectorSell4,000$35.17$140,680.00View SEC Filing  
9/2/2014Duane DesistoCEOSell20,000$36.30$726,000.00View SEC Filing  
8/1/2014Duane DesistoCEOSell20,000$34.23$684,600.00View SEC Filing  
7/1/2014Duane DesistoCEOSell20,000$40.52$810,400.00View SEC Filing  
7/1/2014R Anthony DiehlGeneral CounselSell1,250$39.65$49,562.50View SEC Filing  
6/11/2014R Anthony DiehlGeneral CounselSell17,871$37.09$662,835.39View SEC Filing  
6/9/2014Peter DevlinInsiderSell12,314$37.10$456,849.40View SEC Filing  
4/8/2014Peter DevlinInsiderSell30,000$41.25$1,237,500.00View SEC Filing  
4/3/2014R Anthony DiehlGeneral CounselSell4,617$48.67$224,709.39View SEC Filing  
3/6/2014R Anthony DiehlGeneral CounselSell12,458$49.28$613,930.24View SEC Filing  
3/6/2014Tracey Haas WielinskiVPSell8,275$49.21$407,212.75View SEC Filing  
2/3/2014Charles LiamosDirectorSell11,037$42.93$473,818.41View SEC Filing  
2/3/2014Duane DesistoCEOSell20,000$42.95$859,000.00View SEC Filing  
2/3/2014Peter DevlinInsiderSell30,000$42.82$1,284,600.00View SEC Filing  
1/3/2014Charles LiamosCOOSell86,000$36.02$3,097,720.00View SEC Filing  
1/2/2014Duane DesistoCEOSell20,000$36.07$721,400.00View SEC Filing  
12/3/2013Charles LiamosCOOSell63,808$36.26$2,313,678.08View SEC Filing  
11/18/2013Charles LiamosCOOSell80,000$35.60$2,848,000.00View SEC Filing  
9/3/2013Duane DesistoCEOSell20,000$33.38$667,600.00View SEC Filing  
8/29/2013Sally CrawfordDirectorSell9,000$33.42$300,780.00View SEC Filing  
8/15/2013Regina SommerDirectorSell5,000$33.32$166,600.00View SEC Filing  
8/1/2013Duane DesistoCEOSell20,000$31.85$637,000.00View SEC Filing  
7/1/2013Duane DesistoCEOSell20,000$31.51$630,200.00View SEC Filing  
7/1/2013Peter DevlinInsiderSell30,000$31.48$944,400.00View SEC Filing  
6/14/2013Sally CrawfordDirectorSell31,000$30.47$944,570.00View SEC Filing  
6/10/2013R Anthony DiehlGeneral CounselSell38,455$30.50$1,172,877.50View SEC Filing  
6/3/2013Duane DesistoCEOSell20,000$29.76$595,200.00View SEC Filing  
12/3/2012Brian K RobertsCFOSell10,000$21.92$219,200.00View SEC Filing  
11/1/2012Brian K RobertsCFOSell10,000$21.49$214,900.00View SEC Filing  
9/4/2012Brian K RobertsCFOSell10,000$20.78$207,800.00View SEC Filing  
9/4/2012Duane DesistoCEOSell20,000$20.97$419,400.00View SEC Filing  
9/4/2012Ruthann DepietroVPSell1,000$20.90$20,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Insulet Corporation (NASDAQ:PODD)
Latest Headlines for Insulet Corporation (NASDAQ:PODD)
Source:
Loading headlines, please wait.

Social

Chart

Insulet Corporation (PODD) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.